Afya Limited reported strong financial results for Q3 2025, with revenue increasing 10.4% YoY to R$928.5 million and Adjusted EBITDA growing 14.6% YoY to R$398.9 million. For the nine months ended September 30, 2025, revenue increased 13.4% YoY to R$2,784.3 million, and Adjusted EBITDA rose 18.5% YoY to R$1,291.7 million.
The company reaffirmed its full-year 2025 guidance, projecting revenue between R$3,670 million and R$3,770 million and Adjusted EBITDA between R$1,620 million and R$1,720 million.
As of September 30, 2025, Afya's Net Debt (excluding IFRS 16) decreased to R$1,342.2 million, a reduction of R$472.7 million from December 31, 2024, driven by solid cash flow from operating activities which reached R$1,291.5 million for the nine-month period. The Operating Cash Conversion ratio was 101.5%.
Subsequent to the quarter, Afya issued R$1,500 million in commercial notes on October 15, 2025, and repurchased all 150,000 Series A perpetual convertible preferred shares for R$831,600 on November 3, 2025. The company also received authorization to increase medical school seats by 100, reaching 3,753 total approved medical school seats.

7 days ago

Press Release

Afya Reports Strong Q3 2025 Financials and Outlines Capital Allocation Strategy

AFYA

Earnings

Guidance Update

Debt Issuance

Afya reported strong financial performance for the nine-month period ending Q3 2025, with revenue growing over 13% year-over-year to R2,784 million, adjusted EBITDA increasing almost 19% to R1,292 million, and basic EPS rising 20% to BRL6.40.
The company maintained its leadership in medical education with 3,753 approved medical seats and over 25,000 undergrad medical students, a 6% year-over-year increase. The medical school net average ticket, excluding acquisitions, increased by 3.4% for the nine months.
In October 2025, Afya executed a liability management strategy by issuing commercial notes to prepay debentures and repurchase SoftBank's preferred shares, extending gross debt duration to 3.2 years.
For 2026, the company expects its effective tax rate to converge to 15% due to Pillar Two taxation and anticipates a 5% to 5.2% tuition increase for the 2026 intake cycle. Management is evaluating capital allocation options including M&A, increased share buybacks, and dividends.

7 days ago

Transcript

Afya Reports Strong Q3 and Nine-Month 2025 Financial Results

AFYA

Earnings

Debt Issuance

Revenue Acceleration/Inflection

For the nine-month period ended September 30, 2025, Afya reported revenue of R$2,784.3 million, a 13.4% year-over-year increase, and Adjusted EBITDA of R$1,291.7 million, up 18.5% year-over-year.
In Q3 2025, revenue reached R$928.5 million and Adjusted EBITDA was R$398.9 million, with an Adjusted EBITDA Margin of 43.0%.
Net income for the nine-month period was R$593.0 million, representing a 19.9% year-over-year increase, and earnings per share stood at R$6.40.
Operationally, Afya had 25,706 medical school students and approximately 304,000 users across its ecosystem at the end of Q3 2025.
Post-quarter, on October 15, 2025, Afya issued R$1.5 billion in new debentures to fund the repurchase of Softbank preferred shares and prepay existing debentures, with gross debt totaling R$2,339 million as of Q3 2025.

7 days ago

Presentation

Afya Limited Reports Q3 2025 Financials and Key Strategic Developments

AFYA

Earnings

M&A

Debt Issuance

For the nine-month period ended September 30, 2025, Afya Limited reported revenue of R$2,784,265 thousand and net income of R$592,999 thousand.
As of September 30, 2025, the company's cash and cash equivalents totaled R$996,826 thousand, with total equity reaching R$4,786,592 thousand.
Afya expanded its medical school capacity through the acquisition of Faculdade Masterclass Ltda. (FUNIC) in May 2025, adding 60 medical school seats, and further increased its total approved medical school seats to 3,753 by November 7, 2025.
Subsequent to the quarter, Afya Brazil issued R$1,500,000 thousand in commercial notes on October 15, 2025, and repurchased all 150,000 Series A perpetual convertible preferred shares for R$831,600 thousand on November 3, 2025.
The company recognized an additional income tax expense of R$84,419 thousand for the nine-month period ended September 30, 2025, due to the new Pillar Two global minimum tax, which it is challenging legally.

7 days ago

6-K

Afya Announces Q3 and Nine Months 2025 Financial Results

AFYA

Earnings

Debt Issuance

Share Buyback

Afya Limited reported strong Q3 2025 financial results, with Revenue increasing 10.4% year-over-year to R$928.5 million and Adjusted EBITDA growing 14.6% to R$398.9 million, achieving a 43.0% margin.
For the nine months ended September 30, 2025, Revenue rose 13.4% year-over-year to R$2,784.3 million, and Adjusted EBITDA increased 18.5% to R$1,291.7 million, with a 46.4% margin.
Net Income for Q3 2025 increased 28.4% to R$159.4 million, and Basic EPS for the nine-month period reached R$6.40, up 19.7% year-over-year.
The company reaffirmed its Full Year 2025 Guidance and maintained a solid cash position of R$996.8 million as of September 30, 2025, with an Operating Cash Conversion ratio of 101.5%.
Subsequent to the quarter, Afya issued R$1.5 billion in commercial notes, repurchased R$831.6 million in Series A preferred shares, and fully repaid R$500 million in debentures, while also approving a new share repurchase program for up to 4,000,000 Class A common shares.

7 days ago

6-K

Afya Expands Medical Education Capacity

AFYA

New Projects/Investments

Debt Issuance

Share Buyback

Afya Limited received authorization to add 100 new medical seats at its ITPAC Porto Nacional campus, increasing the company's overall approved medical seats to 3,753.
Despite strong revenue growth and profitability, Afya's Altman Z-Score of 2.05 indicates some financial stress, and the company has issued BRL 134.518 million in new debt over the past three years.
Analyst sentiment is cautiously optimistic, with a Buy rating and a $25.50 price target, supported by robust revenue growth, cost management, and strategic initiatives including a share repurchase program.

Nov 8, 2025, 4:09 AM

Morningstar

Afya Limited Announces Medical Seats Increase

AFYA

New Projects/Investments

Afya Limited announced on November 7, 2025, that the Ministry of Education authorized an increase of 100 medical seats at its AFYA Faculdade de Ciências Médicas Bragança campus.
This authorization brings the total medical seats at the Bragança campus to 150.
The company's total approved medical seats across all campuses now stands at 3,753.
Afya is recognized as the leading medical education group in Brazil based on the number of medical school seats.

Nov 7, 2025, 1:15 PM

6-K

Afya Reaffirms 2025 Guidance and Details Strategic Growth Initiatives

AFYA

Guidance Update

Debt Issuance

New Projects/Investments

Afya reaffirmed its 2025 guidance for Revenue and Adjusted EBITDA, demonstrating consistent financial performance.
The company is the largest hub of medical education and solutions in Brazil, operating 33 medical school campuses and serving 25,733 medical students.
Afya reported strong operating cash generation and consistent deleveraging, with its Net Debt/Adjusted EBITDA ratio falling to 0.97 in 1H25.
Strategic growth areas include the expansion of continuing education, with revenue reaching R$255.4 million and 50,521 students in 2024, and significant investments in AI-powered solutions for medical education and practice.
The company executed a liability management strategy by issuing a R$1.5 billion new debenture to increase debt duration and reduce the cost of debt, alongside the early settlement of the Softbank convertible.

Oct 22, 2025, 12:00 PM

Presentation

Afya Investor Day 2025: Innovation, Growth, and Capital Strategy

AFYA

Guidance Update

New Projects/Investments

Debt Issuance

Afya reported a strong financial track record since its 2019 IPO, with 2024 net revenue reaching BRL 3.3 billion and adjusted EBITDA at BRL 1.4 billion, and provided 2025 guidance of BRL 3.7 billion - BRL 3.8 billion for net revenue and BRL 1.6 billion - BRL 1.7 billion for adjusted EBITDA.
The company is expanding its ecosystem with new digital solutions for physicians, including Afya Play, Afya Assist, White Book AI, and iClinic, alongside a new financial marketplace offering Afya Pay, anticipated payment, pension plans, and insurance.
Afya has actively pursued inorganic growth with 22 acquisitions since its IPO, allocating BRL 4.5 billion for these, and announced a BRL 1.5 billion debenture issuance to prepay SoftBank debt, aiming to optimize debt structure and cost.
The company demonstrated commitment to shareholder returns by paying dividends for the first time in April 2025 (BRL 130 million) and announcing its fifth share repurchase program in August 2025.

Oct 22, 2025, 12:00 PM

Transcript

Afya Subsidiary Announces R$1.5 Billion Debenture Issuance

AFYA

Debt Issuance

Convertible Preferred Issuance

Afya's wholly owned subsidiary, Afya Participações S.A., has approved the first issuance of book-entry commercial notes with an aggregate principal amount of R$1,500.0 million.
The issuance is divided into two series: a R$500.0 million First Series maturing on October 15, 2028, and a R$1,000 million Second Series maturing on October 15, 2030.
The First Series will bear interest at the Brazilian daily interbank deposit rate plus 0.70%, while the Second Series will have an interest rate of the Brazilian daily interbank deposit rate plus 0.85%.
Afya plans to use the net proceeds for general corporate purposes, including the optional full early redemption of Afya Brazil\u2019s first debenture issuance and the repurchase of Series A perpetual convertible preferred shares.

Oct 9, 2025, 11:28 PM

Press Release

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for AFYA.

No recent filings or transcripts found for AFYA.